{
}
The Global Uveitis Treatment market is projected to grow from USD 725 million in 2024 to USD 1.28 billion by 2032, with a CAGR of 8.5%. The study covers various treatment types, including corticosteroids and biologic agents, and offers customization options for regional and application-specific analysis. Key players include Novartis, Pfizer, and AbbVie, with North America leading the market and Asia-Pacific identified as the fastest-growing region.
Prothena's stock surged nearly 40% after promising results from a midstage study of its Parkinson's treatment, prasinezumab, partnered with Roche. Although the drug missed its primary goal, it showed a delay in motor worsening, particularly in patients using levodopa, suggesting potential for future trials. Analysts estimate Prothena could earn up to $275 million in royalties, despite concerns about the drug's modest efficacy and administration challenges.
Roche's Phase IIb PADOVA study of prasinezumab in early-stage Parkinson's disease did not meet its primary endpoint of time to confirmed motor progression, though it showed promising trends in secondary endpoints, particularly in patients also treated with levodopa. The drug was well tolerated with no new safety concerns reported. Roche plans to present full results at an upcoming medical meeting, emphasizing the need for further exploration in the absence of disease-modifying treatments for Parkinson's.
Roche's Phase IIb PADOVA study of prasinezumab in early-stage Parkinson's disease failed to meet its primary endpoint, with a hazard ratio of 0.84 (p=0.0657). However, a more significant effect was noted in patients treated with levodopa (HR=0.79). The treatment was well tolerated, with no new safety concerns reported.
Xcovery Holdings' ensartinib, branded as Ensacove, has received FDA approval as a first-line treatment for ALK-positive non-small cell lung cancer, marking a significant milestone as the first innovative targeted lung cancer drug from a Chinese company to enter the U.S. market. While it shows a 44% reduction in progression or death compared to Pfizer's Xalkori, it faces stiff competition from established ALK inhibitors like Roche's Alecensa, which has demonstrated superior efficacy in previous studies. Despite its potential, Ensacove's market entry comes amid a landscape dominated by major pharmaceutical players.
Roche's Parkinson's drug, prasinezumab, has failed a Phase IIb trial, despite showing potential clinical efficacy in delaying motor progression. While the results indicated positive trends in secondary endpoints, they lacked statistical significance, prompting analysts to call the data "promising but leaves uncertainty." Roche plans to continue related studies and may consider a new trial to further explore the findings.
Roche and Prothena's Parkinson's antibody treatment, prasinezumab, failed to meet its primary endpoint in the phase 2b PADOVA study, although it showed a 16% delay in motor progression compared to placebo. The drug was well tolerated, and Roche plans to further evaluate the data and collaborate with health authorities on next steps. Parkinson's disease remains difficult to treat, with many therapies struggling to progress through clinical trials.
Roche's experimental Parkinson's drug, prasinezumab, failed to meet its primary goal in a mid-stage trial, not significantly delaying motor symptom progression in early-stage patients. Despite this setback, the drug showed potential clinical efficacy and positive trends in other trial objectives. Roche plans to further evaluate the data and collaborate with health authorities on next steps.
Roche's candidate drug for Parkinson's disease has failed to meet a crucial objective in a mid-stage clinical trial. This setback raises concerns about the drug's potential effectiveness and the company's future prospects in the competitive Parkinson's treatment market.
Roche announced that prasinezumab, an experimental therapy developed with Prothena Corporation for Parkinson’s disease, failed to meet the primary endpoint in its Phase IIb PADOVA trial for early Parkinson's disease. Despite this setback, Prothena's stock experienced gains.
Hoffmann-La Roche AG
Companies
The information provided herein is generated by experimental artificial intelligence and is for informational purposes only.
global uveitis treatment market poised for significant growth by 2032
Pfizer Inc.
Bayer AG
Novartis AG
Regeneron Pharmaceuticals, Inc.
Merck & Co., Inc.
CIPLA LTD
Lupin Limited
Hoffmann-La Roche AG
Bausch Health Companies Inc.
BIOGEN
ABBVIE
Alimera Sciences Inc.
SAU
ISR
FRA
RUS
DEU
TWN
ARG
ARE
AUT
TUR
SGP
NZL
CHL
USA
BRA
CAN
ITA
JPN
IDN
GBR
ESP
IND
MYS
COL
AUS
THA
EGY
VNM
KOR
PHL
CHN
ZAF
MEX
Nidhi Bhavsar
Show more
20:41 19.12.2024
Prothena stock jumps nearly 40 percent on promising Parkinson's treatment results
18:28 19.12.2024
Roche's prasinezumab shows mixed results in Parkinson's disease study
16:53 19.12.2024
roche's prasinezumab study shows potential but misses primary endpoint
16:50 19.12.2024
China's ensartinib gains FDA approval for lung cancer treatment
United States Dollar
Chinese Yuan
Swiss Franc
Japanese Yen
AstraZeneca PLC
Hoffmann-La Roche AG
Pfizer Inc.
Novartis AG
CHN
USA
JPN
Show more
16:20 19.12.2024
Roche's Parkinson's drug prasinezumab fails to achieve significant trial results
15:54 19.12.2024
roche and prothena's parkinsons antibody treatment fails in phase 2 trial
United States Dollar
UCB SA
Hoffmann-La Roche AG
Prothena Corp PLC
Novartis AG
BIOGEN
IRL
Levi Garraway
Show more
15:39 19.12.2024
Roche's Parkinson's drug fails to meet primary trial objectives
14:44 19.12.2024
roche's parkinsons drug candidate fails to meet mid-stage study goal
14:33 19.12.2024
Prothena stock rises despite Roche's Parkinson's therapy trial failure
14:31 19.12.2024
Trending
Subcategory
Corporate News
Industry Trends
Startups & Entrepreneurship
Retail and Consumer Goods
Supply Chain Management
Global Trade Developments
Stock Market Updates
Government Economic Policies
Industry Mergers & Acquisitions
Energy Sector Developments
Workplace Trends
Funding Rounds & Investments
CEO Changes
AI Applications
Private Equity Deals
Emerging Startups
Fintech Startups
AI Innovations
Global Financial Events
Central Bank Actions
Countries:
Companies:
Apple Inc.
Google Inc.
Tesla, Inc.
Amazon.com, Inc.
Microsoft Corporation
Tesmec S.p.A.
Alphabet Inc.
OpenAI ERC USD
Walmart Inc.
SWIGGY LIMITED
TENCENT
NVIDIA Corporation
Foxconn Technology Co., Ltd.
Hollywood Bowl Group PLC
NASDAQ Composite
Wise plc
Mastercard Inc
Bose Corporation
Mistral 1
Fast Retailing Co., Ltd.
Currencies:
United States Dollar
Indian Rupee
Chinese Yuan
Euro
Japanese Yen
British Pound Sterling
United Arab Emirates Dirham
Vietnamese Đồng
South Korean Won
New Zealand Dollar
Saudi Riyal
Thai Baht
Australian Dollar
Indonesian Rupiah
Singapore Dollar
Omani Rial
Bahraini Dinar
Qatari Riyal
Algerian Dinar
Egyptian Pound
People: